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ABSTRACT 
As a catastrophe of serious medical and social significance, HIV/AIDS comes with dire consequences. The pandemic has been with us and is causing high 
mortality with no regard for age, race or societal status. Now into the third decade, we have seen advances in the treatment of infected persons yet, the 
pandemic rages on with millions of new infections occurring annually. The HIV vaccine has been elusive and quest for it disappointing and frustrating, 
prompting some to wonder if there will ever be an effective vaccine or not. A lot of information and campaigns is on about HIV prevention; leaving much to 
be desired in the areas of core HIV research, discoveries and other interventions. We have revealed some steps taken so far and where we stand at the moment. 
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INTRODUCTION          
The  Human  Immunodeficiency  Virus  is  a  lentivirus 
belonging  to  the  family  Retroviridae.  The  novelty  and 
intrinsic importance of retroviruses have been underlined by 
the award of the prestigious Nobel Prize on no less than three 
separate occasions. Although initially controversial, was the 
iconoclastic  proposal  by  Howard  Temin  that  genetic 
information could flow “against the tide” from RNA to DNA, 
which  was  unequivocally  confirmed  by  the  subsequent 
independent  discovery  in  1970  by  Temin  and  David 
Baltimore of the enzyme reverse transcriptase in retroviruses, 
for which they both shared the Nobel Prize in medicine and 
physiology  in  1975.  In  1981,  HIV  was  discovered 
independently by Luc Montagnier an American and Francois 
Barre Sinoussi a Frenchman, both of who shared the Nobel 
Prize in 2008 with Harold Zur Hausen 
1.  
HIV exists in two immunological forms, HIV-1 and HIV-2. 
HIV-1 is divided into two phylogenetic groups: M (major) 
and O (outlier). Group M is further subdivided into subtypes 
A to K with two circulating recombinant forms AE and AG 
while HIV-2 is divided into subtypes A to E 
2. Although the 
first  case  of  AIDS  was  described  as  recently  as  1981,  the 
pandemic has escalated at such a rate that by 1993 the World 
Health  Organization  estimated  that  over  13million  young 
adults had been infected with HIV and over 2million already 
developed AIDS, most of whom had died 
3. The threat posed 
by AIDS has triggered an unprecedented effort by researchers 
and  governments  alike  to  understand  and  conquer  this 
disease. Already, a lot is known about HIV than about any 
other virus of longer standing. Indeed, HIV now sets the pace 
in virus research. New concepts and techniques pioneered by 
HIV virologists are now being employed in every area of the 
discipline –from the regulation of viral replication, through 
molecular pathogenesis, to laboratory diagnostic methods and 
novel approaches in viral therapy and vaccinology 
4. 
ORIGIN OF HIV      
The origin of HIV and AIDS has puzzled scientists ever since 
the illness first came to light in the early 1980s. The most 
recognized case of AIDS occurred in the USA in the early 
1980s 
5. A number of gay men in New York and California 
suddenly began to develop rare opportunistic infections and 
cancers that were stubbornly resistant to any treatment. At 
this  time,  AIDS  did not  yet  have  the  name  but  it  quickly 
became  obvious  that  all  the  men  were  suffering  from  a 
common syndrome 
6. The discovery of HIV was made soon 
after 
7. It is now generally accepted that HIV is a descendant 
of the Simian immunodeficiency virus because certain strains 
of SIVs bear close resemblance to HIV-1 and HIV-2, the two 
types of HIV 
8. In February 1999 a group of researchers from 
the University of Alabama announced they had found a type 
of  SIVcpz  that  was  identical  to  HIV-1.  This  strain  was 
identified in a frozen sample taken from a captive member of 
the  sub-group  of  chimpanzees  known  as  Pan  Troglodytes 
which  were  once  common  in  West  Africa 
9.  Their  final 
findings were published two years later in Nature magazine 
10. 
POSSIBILITY  OF  INTERSPECIES  TRANSMISSION 
OF HIV      
Many  theories  have  been  proffered  for  how  HIV  crossed 
from  primates  to  humans.  Firstly  and  most  commonly 
accepted  is  the  “hunter”  theory.  Retroviral  transfer  from 
primates to hunters is still occurring even today. In samples 
from 1099 individuals in Cameroun, it was discovered that 10 
(1%)  were  infected  with  Simian  Foamy  Virus  (SFV)  an 
illness which like SIV was previously thought only to infect 
primates through butchering and consumption of monkey and 
ape meat. Discoveries such as this have led to calls for an 
outright ban on bushmeat hunting to prevent simian viruses 
being passed to humans 
11.  
Secondly some rather controversial theories have attributed it 
to  being  transferred  iatrogenically  (medical  interventions) 
and that the oral polio vaccine played a role. In his book The 
River, Edward Hooper suggested that HIV could be traced to 
an  oral  polio  vaccine  called  “chat”  given  to  millions  of 
people in Africa in the late 1950s which was grown in kidney 
cells of chimpanzees infected with SICcmz. This position has 
been criticized by many who feel that the oral administration 
of the vaccine is insufficient to cause HIV because SIV/HIV 
need to be directly introduced into the bloodstream to cause 
infection and that the lining of the mouth and throat generally Onoja A.B et al: HIV: A Raging Beast 
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act  as  barriers
  12.  In  April  2001,  the  Wistar  Institute  in 
Philadelphia (one of the manufacturers of the chat) vaccine 
announced no trace of HIV in the vial of polio vaccines used 
in the programme 
13. A second analysis confirmed that only 
macaque monkeys kidney cells which cannot be infected with 
SIV or HIV was used to make chat 
14.   
Thirdly, the contaminated needle theory is an extension of the 
original  “hunter”  theory.  In  the  1990s,  African health  care 
professionals  working  on  inoculation  and  other  medical 
program were in the habit of using single syringes to inject 
multiple patients as they could not afford the huge quantities 
of  syringes  needed  due  to  the  cost.  This  would  have 
transferred any viral particles within a hunter’s blood from 
one person to another 
15.  
Fourthly, “the colonialism or Heart of Darkness” theory is 
one of the most recent to have entered into the debate. This is 
still on the “hunters” premise but explains how this original 
infection could have led to an epidemic. In the 19
th and early 
20
th century, much of Africa was ruled by  colonial forces. 
Their rule was harsh and in areas such as French Equatorial 
Africa and the Belgian Congo, many Africans were forced 
into labor camps where sanitation was poor, food was scarce 
and  physical  demands  were  extreme.  These  factors  are 
sufficient to create poor state of health in anyone so that SIV 
could easily have infiltrated the labor force and mutated to 
HIV in a weakened immune system 
16. Also, it was believed 
that many laborers would have been inoculated with unsterile 
needles  against  diseases  (to  keep  them  alive  and  working) 
and that many camps actively employed prostitutes to keep 
their  workers  happy  creating  numerous  possibilities  for 
onward transmission 
17.  
Fifthly, is “the conspiracy” theory in which many believed 
was  man-made.  A  recent  survey  carried  out  in  the  USA 
identified  a  significant  number  of  African-Americans  who 
believe HIV was manufactured as part of a biological warfare 
programme, designed to wipe out large numbers of black and 
homosexuals 
18. 
CROSS  REACTIVITY BETWEEN HIV  AND  SIMIAN 
IMMUNODEFICIENCY VIRUS (SIV)  
HIV-1  and  HIV-2  are  believed  to  be  the  result  of  cross-
species  transmission  from  Simian Immunodeficiency  Virus 
(SIV)  –infected  chimpanzees  and  sooty  mangabeys 
respectively, which represent two (SIVcpz and SIVsm) of the 
six major lentiviral phylogenetic lineages 
19,20. No evidence 
exists that SIV strains from the remaining nonhuman primate 
lineages  have  infected  humans,  although  many  grow  in 
human cells invitro as do SIVcpz and SIVsm. Although SIV 
sequences  were  not  identified  in  either  case,  the  findings 
suggests  that  humans  are  probably  exposed  to  different 
simian  retroviruses  that  can  establish  new  infections  in 
humans.  Nonhuman  primates  infected  with  SIV  from  the 
currently  recognized  lineages  can  harbor  antibodies  that 
serologically cross-react with some HIV-1 or HIV-2 antigens 
21. The potential exists for zoonotic transmission of diverse 
primate  lentiviruses  in  many  parts  of  sub-saharan  Africa 
including  the  Congo  River  Basin 
22.  This  potential  is 
supported by the identification of a Cameroonian man whose 
HIV serologic results were indeterminate but whose serum 
specimen reacted strongly and exclusively with an SIVmnd 
V3 loop peptide 
23. An even more compelling case for cross-
species is the recent finding of a Cameroonian man who may 
have been exposed to a colobus SIV, as indicated by a strong 
humoral (envIDR and V3) and a weak cellular (gag) immune 
response 
24. In many cases, HIV western blots (WBs) with 
indeterminate  profiles  of  SIV-infected  monkeys  resemble 
those of HIV enzyme immunoassay (EIA) -positive, WB –
indeterminate  human  sera  from  Africa.  In  general,  such 
indeterminate African sera from persons in the United States 
25-27. These data suggests that the WB –indeterminate patterns 
in HIV EIA –reactive sera from persons living in Africa may 
reflect more than just a recent HIV infection or an infection 
with a highly divergent HIV-1 strain; they may reflect either 
cross-reactivity with unknown pathogens of African origin or 
exposure to new HIV- or SIV- like strains 
28.  
FACTORS THAT LEAD TO THE SPREAD OF HIV   
Reasons  have  been  advanced  for  the  spread  of  the  virus 
among which are:-   
Gender inequity and violence to women 
In South Africa, women who have experienced physical or 
sexual intimate partner violence or are in relationships with 
low equality are at a greater risk of HIV infection compared 
with women who do not experience these situations. Also, 
men who have been physically  violent toward partners are 
more likely to be infected with HIV 
29. Young women who 
have experienced sexual abuse in childhood are also at two-
thirds greater risk of HIV infection 
30.  
Sex trade 
In sub-Saharan Africa, India and many parts of the world, the 
HIV epidemic remains substantially driven by contacts with 
commercial sex workers 
31.    
Cultural practices 
In  developing  countries,  many  are  exposed  to  risky 
traditional practices such as scarification in which incisions 
are  made.  When  this  is  done  for  many  people  without 
sterilization,  the  sharp  objects  used  spreads  HIV.  Local 
manicurist and pedicurists use locally fabricated scissors and 
tools which make them culpable in the spread of HIV if not 
properly  sterilized.  Risky  sexual  behaviors  such  as 
indiscriminate sexual intercourse, high promiscuity  without 
using protection also results in the infection. Groups at higher 
risk  of  infection  are  homosexuals,  male  and  female 
prostitutes, injection drug users, blood transfusion recipients, 
children  born  to  HIV  infected  mothers  and  heterosexual 
contacts of HIV infected individuals 
2. 
SEXUALLY  TRANSMITTED  CO-INFECTIONS 
AMONG HIV-INFECTED                                                                                     
Human  Immunodeficiency  Virus-infected  victims  are  more 
likely  infected  with  other  sexually  transmitted  infections 
specifically  syphilis  and  hepatitis  B 
32.  The  incidence  of 
herpes  simplex  virus-2  reduced  by  one-third  following  a 
change  in  the  sexual  behavior  of  men  including  less 
perpetration of intimate partner violence 
33. 
EFFECTS OF HIV-1 ON MALARIA INCIDENCE 
 HIV-1 infection increases the risk of and severity of malaria 
34,35. The best evidence for association between HIV-1 and 
clinical malaria comes from 2 longitudinal studies in Uganda 
where  malaria  transmission  is  of  high  intensity.  A 
community-based study in rural Masaka found odds ratios of 
clinical  malaria  among  HIV-positive  adults  compared  to 
HIV- negative adults, of 1.2, 3.4 and 6.0 for CD4 counts of 
≥500µl,  >200-499/µl  and  >200/µl  respectively 
36.  In 
Kinshasa,  HIV-1  infection  at  any  stage  and  clinically 
diagnosed AIDS increased malaria incidence by 1.2- and 2-
fold respectively but the increases were not significant 
37. A 
birth  cohort  in  Blantryre,  Malawi  found  no  HIV-related 
increase  in  the  incidence  of  parasitemia 
38.  In  Kampala, Onoja A.B et al: HIV: A Raging Beast 
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perinatally  HIV-infected  children  with  AIDS  experienced 
notably fewer malaria episodes than HIV-infected children 
39 
which were attributed to increased use of chloroquine before 
hospitalization among the HIV-infected. In contrast, among 
children in Kinshasa from 1986 to 1988 who had received 
blood  transfusions,  those  who  were  HIV-infected 
experienced 1.4 times more clinical malaria than those who 
were not 
40. The observed effect of HIV-1 on the incidence of 
clinical  malaria  may  in  part  be  the  result  of  an  increased 
incidence of recrudescence after the efficacy of anti-malarial 
treatment 
41,42. 
ABC OF HIV     
Prevention programmes have focused  on behaviour change 
since  the  early  1990s,  using  “ABC”  as  an  acronym  for 
protective  behaviours:  Abstinence,  Be  faithful,  Condoms. 
Majority  of  programmes  for  young  people  promote 
abstinence and fidelity, with condoms as a fall-back option if 
sex  happened.  ABC  has  been  criticised  by  many  HIV 
prevention practitioners as being over-simplistic and a reason 
for limited success 
43.
 But the US Government saw a different 
set of weaknesses in the ABC method. They perceived that 
condoms  were  being  promoted  to  young  and  old 
indiscriminately, to the detriment of abstinence and fidelity 
messages. This was thought to be disrespectful to the values 
of  local  faiths  and  traditions,  particularly  in  relation  to 
women. Also, evidence from the high prevalence, generalised 
epidemics in Uganda and Botswana in the 1990s seemed to 
show  that  the  impact  of  condoms  on  the  epidemic  as 
compared to partner reduction and delayed sexual debut was 
limited.  This  was  thought  to  be  partly  because  people  in 
regular partnerships were considered to be reluctant to use 
condoms, and because it was logistically difficult to ensure 
they were widely available to enable regular and consistent 
use 
44.
 There were also concerns that educating young people 
about  condoms  would  reduce  the  effectiveness  of  the 
abstinence message and cause harm if condoms were then not 
consistently available 
45.   
Studies overwhelmingly demonstrate that condoms are highly 
effective in preventing HIV transmission. An evaluation of 
existing published evidence shows that correct and consistent 
use of male condom reduces the risk of HIV infection by at 
least  90%.  All  the  evidence  on  condom  promotion  and 
distribution programmes indicates their efficacy at increasing 
condom use and decreasing the prevalence of HIV and STI. 
This makes condom promotion and distribution one of the 
most effective prevention programmes that exists 
46.
 Whilst it 
is true that we do not yet know enough about the complex 
role  of  condoms  as  a  public  health  measure  in  high 
prevalence  generalised  epidemics,  we  know  enough  to  say 
that they are an essential component of any HIV prevention 
programme.  The  female  condom  provides  women  with 
another type of condom for the prevention of pregnancy and 
STI/HIV,  which  they  can  use  themselves.  This  is  a  key 
method for the empowerment of women and has also been 
shown  to  be  effective  in  reducing  the  risk  of  HIV 
transmission 
47. 
GLOBAL RESPONSE TO HIV IN AFRICA   
The WHO Global programme for the fight against AIDS was 
swiftly put into action and aimed to raise $1.5billion a year 
by the end of the decade to help prevention and educational 
efforts 
48, with priority to Africa 
49. In 1996, UNAIDS was 
established  to  take  responsibility  for  coordinating 
international action against the epidemic 
50,51. In 2000, after 
mounting pressure to make HIV/AIDS drugs more accessible 
to  Africans,  five  pharmaceutical  companies  offered  to 
negotiate steep reductions in the prices of the drugs for Africa 
and other poor regions 
52. At last it seemed that the world was 
sitting up and taking notice of the ravaging AIDS epidemic in 
Africa.  The  amount  of  money  that  western  nations  were 
willing  to  give  to  help  scale-up  treatment  for  those  living 
with AIDS in Africa greatly increased in the new millennium. 
In 2001, the Global Fund to Fight AIDS, Tuberculosis and 
malaria was created 
53-55 and two  years later United States 
President George Bush announced the President’s Emergency 
Plan for AIDS Relief (PEPFAR) 
56. Between 2001 and 2004, 
global  funding  for  AIDS  in  low-middle  income  countries 
trebled to $6.1billion a year. UNAIDS estimated this to be 
50% of all AIDS spending in sub-Saharan Africa during this 
period.  In  2004–2006  the  PEPFAR  budget  increased  from 
$207 million to $322 million, which was to be spent in 15 
countries, 12 of which are in sub-Saharan Africa, including 
Zambia. Fifty five percent of those funds are required to be 
spent  on  treatment  and  10%  on  orphans  and  vulnerable 
children.  Fifteen  percent  are  recommended  to  be  spent  on 
palliative care for HIV+ people and 20% on prevention 
57. 
Prevention must cover blood safety, prevention of mother-to-
child transmission, safe medical injections, AB activities and 
“other prevention”. PEPFAR country teams are required to 
spend  half  of  prevention  funds  on  prevention  of  sexual 
transmission,  two-thirds  of  which  should  be  spent  on  AB 
(abstinence/faithfulness) activities 
57. 
Very recently, the United States Department of Health and 
Human  Services  in  partnership  with  the  U.S.  President’s 
Emergency  Plan  for  AIDS  Relief  (PEPFAR)  planned  an 
investment  of  $130million  over  a  five  year  period  to 
transform  African  medical  education  and  dramatically 
increasing  the  number  of  health  care  workers.  Eleven 
programmatic awards each worth $10million, largely funded 
by PEPFAR will expand and enhance medical education and 
research training in the field of HIV/AIDS 
58.   
VACCINE STUDIES 
Vaccines have been among the most effective public health 
interventions. Although a classic preventive vaccine remains 
the ultimate goal, the enormous genetic diversity and other 
unique  features  of  the  HIV  envelope  protein  have  thus 
thwarted attempts to identify an effective candidate. Based on 
studies of HIV pathogenesis in humans and animal models, 
vaccines  that  induce  strong  T-cell  mediated  immune 
responses  even  if  infection  is  not  completely  prevented. 
Vaccine-induced T-cell responses may  blunt initial viremia 
and  prevent  the  early  and  massive  destruction  of  memory 
CD4
+ T cells that help control infection and prolong disease-
free survival 
59. The initial empirical approach of immunizing 
with VaxGen’s AIDSVax, a recombinant form of the outer 
glycoprotein -120(gp120) protein of the HIV envelope which 
was based on a strategy that was successful with hepatitis B 
virus, failed to protect volunteers from Infection, apparently 
because  the  vaccine  did  not  induce  broadly  neutralizing 
antibodies 
60. 
Cytotoxic  (CD8
+)  T  lymphocytes,  key  effectors  of  cellular 
immunity  recognize  viral  peptides  bound  to  major-
histocompatibility-complex (MHC) molecules on the surface 
of  virus-infected  cells 
61.  They  can  kill  or  suppress  cells 
infected with HIV in the laboratory 
62, and the emergence of 
these  lymphocytes  correlates  with  early  containment  of 
viremia 
63. If natural-history and animal-model studies prove Onoja A.B et al: HIV: A Raging Beast 
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to be predictive, people who receive T-cell vaccines before 
infection might remain disease-free for a prolonged period, 
and  antiretroviral  therapy  which  can  be  burdensome  with 
serious side effects over time, might be delayed. Futhermore, 
if initial infection is blunted and memory CD4
+ T cells in gut-
associated  lymphoid  tissue  are  preserved,  strong,  vaccine-
induced T-cell-mediated immune responses might draw down 
viral reservoirs by destroying HIV-infected cells before new 
viral particles are released 
64. 
CHALLEGES OF HIV VACCINES 
A  vaccine  that  conforms  to  the  classic  paradigm  of  viral 
vaccines  remains  the  goal  of  efforts  to  develop  an  HIV 
vaccine. Such a vaccine would induce immune responses that 
prevent the establishment of HIV infection by clearing virus 
before latent viral reservoirs are produced. This goal may not 
be  realized  with  first-generation  vaccines.  Futhermore,  the 
window of opportunity for the immune system to clear the 
initial  infection  is  narrow,  since  HIV  integrates  and 
establishes latent infection within days or weeks. This aspect 
of HIV infection puts it in sharp contrast with almost all other 
viral infections in which the initial rounds of viral replication 
do not establish a permanent reservoir of infection. For this 
reason, HIV poses greater challenge to the classic vaccination 
paradigm in which prevention of clinically relevant infection 
ultimately  leads  to  the  eradication  of  the  microbe,  even 
though  initial  rounds  of  viral  replication  may  occur  as  a 
result,  rational  and  empirical  approaches  to  vaccine 
development have not been successful to date 
59. Secondly, 
enormous  genetic  diversity  and  mutations  that  occur  with 
replication  enable  HIV  to  avoid  immune  surveillance 
4. 
Thirdly,  conserved  antibody  targets  on  the  outer  envelope 
protein  are  hidden  from  immune  recognition 
65.  Basic 
research  on  the  HIV  envelope  has  since  provided  several 
clues in the effort to determine why induction of antibodies 
that  neutralize  primary  isolates  of  HIV  is  difficult 
66.  The 
envelope on the virion surface exists not as a monomer but as 
a trimer. Immunogenic regions of the monomer are occluded 
in  the  native  trimer  on  the  virion  surface.  The  envelope 
protein  is  cloaked  with  numerous  N-linked  glycans, 
undergoes considerable conformational change on binding to 
the cell-surface CD4 receptor and exposes sequences that are 
highly  variable 
67,68.  The  potential  effect  of  antibodies 
directed against variable regions is negated by the emergence 
of these so-called escape variants 
69,70. This means that high 
levels of neutralizing antibodies may be required to prevent 
infection 
71-73.  The  implications  of  all  these  is  that 
fundamental  questions regarding  HIV  disease  and the host 
response to the virus need to be answered. Also, fresh new 
ideas beyond the scope of classic vaccinology are urgently 
needed 
59. 
THERAPEUTIC INTERVENTION 
In 2001, there were more than 20million people living with 
AIDS in sub-Saharan Africa, but only 8,000 people in the 
entire continent were accessing treatment 
74. Therefore, Kofi 
Anan opined that in the fight against HIV there was no us and 
them, no  developed  and  developing  countries, no  rich and 
poor but only a common enemy that knows no frontiers and 
threatens all people 
75. The development of more than two 
dozen  antiretroviral  therapies  to  combat  HIV  infection has 
resulted in a dramatic decrease in morbidity and mortality in 
developed  countries and, increasingly, in low- and middle- 
income  countries  as  these  therapies  become  more  widely 
available 
59.  Several  national  HIV  treatment  guidelines 
including the Nigeria guideline have recommended treatment 
with  triple  antiretroviral  regimen  when  patients  become 
symptomatic  or  have  CD4
+  <200µl  of  blood.  The  current 
development  of  antiretroviral  therapy  which  includes  new 
agents, new formulas and pharmacokinetics enhancements is 
directed to achieving better potency, higher genetic resistant 
barrier, less pill burden and once a day dosing. These will 
ultimately improve the adherence and long-term effectiveness 
of antiretroviral treatment 
60. 
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